Results 1 to 10 of about 14,668 (165)

Effect of daratumumab on patients with high-risk cytogenetic multiple myeloma: a systematic review and meta-analysis of randomized controlled trials [PDF]

open access: yesFrontiers in Immunology
Although daratumumab has been reported to significantly improve the prognosis of multiple myeloma (MM), its efficacy in patients with cytogenetically high-risk MM (HRMM) remains unclear.
Liang Su   +4 more
doaj   +2 more sources

CD200 immune checkpoint expression is associated with inferior outcome in multiple myeloma patients treated with anti-CD38 monoclonal antibodies

open access: yesOncoImmunology
In multiple myeloma (MM), the anti-CD38 monoclonal antibody Daratumumab has become essential in the therapeutic arsenal, although very few predictive factors of response to Daratumumab have been identified in clinical studies.
Djamila Chemlal   +15 more
doaj   +1 more source

Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma

open access: yesNature Communications
Anti-CD38 monoclonal antibodies like Daratumumab (Dara) are effective in multiple myeloma (MM); however, drug resistance ultimately occurs and the mechanisms behind this are poorly understood.
Jiye Liu   +21 more
doaj   +1 more source

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

open access: yesHaematologica, 2011
Background In our efforts to develop novel effective treatment regimens for multiple myeloma we evaluated the potential benefits of combining the immunomodulatory drug lenalidomide with daratumumab.
Michael. S. van der Veer   +7 more
doaj   +1 more source

Daratumumab in untreated newly diagnosed multiple myeloma

open access: yesTherapeutic Advances in Hematology, 2019
The treatment of multiple myeloma has evolved markedly in the last decade, but mortality remains high, emphasizing the need for more effective therapies.
Nadine Abdallah, Shaji K. Kumar
doaj   +1 more source

Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414)

open access: yesJTO Clinical and Research Reports, 2021
Introduction: The programmed death-ligand 1 inhibitor atezolizumab improves progression-free survival (PFS) and overall survival (OS) for patients with previously treated advanced NSCLC.
Rathi N. Pillai, MD   +12 more
doaj   +1 more source

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

open access: yesHaematologica, 2018
Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical activity in combination with bortezomib and dexamethasone versus bortezomib and dexamethasone alone in the primary analysis of CASTOR, a phase 3 study in relapsed and/or ...
Andrew Spencer   +36 more
doaj   +1 more source

Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?

open access: yesCells, 2020
During a time span of just a few years, the CD38 antibody, daratumumab, has been established as one of the most important new drugs for the treatment of multiple myeloma, both in the relapsed/refractory setting and, more recently, as a first-line ...
Torben Plesner   +2 more
doaj   +1 more source

The real-world outcomes of multiple myeloma patients treated with daratumumab.

open access: yesPLoS ONE, 2021
Most patients cannot be included in randomized clinical trials. We report real-world outcomes of all Danish patients with multiple myeloma (MM) treated with daratumumab-based regimens until 1 January 2019.MethodsInformation of 635 patients treated with ...
Agoston Gyula Szabo   +17 more
doaj   +1 more source

Determinants of response to daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma

open access: yesJournal for ImmunoTherapy of Cancer, 2021
Background The potential therapeutic efficacy of daratumumab in natural killer T-cell lymphoma (NKTL) was highlighted when its off-label usage produced sustained remission in a patient with highly refractory disease.
Jennifer Yang   +15 more
doaj   +1 more source

Home - About - Disclaimer - Privacy